Experience

Brendan is a partner in the firm and his practice focuses on venture capital transactions, mergers and acquisitions, joint ventures, fund formation and general corporate representation for early stage companies.

Brendan’s venture capital practice consists of providing counsel to technology and tech enabled services companies. Brendan’s M&A and joint venture practices are related to his venture capital work, primarily exit events, or companies seeking growth through joint ventures or acquisitions. He regularly represents early stage companies, from formation through exit event and all stages in between, including fundraising, employment matters and the various agreements that emerging companies enter into during growth.

Brendan began his career at Condon & Forsyth, defending international air carriers in mass tort litigation and other accidents.

 

Education

Pace University School of Law (J.D., 1993), where he was a member of the Law Review. 

State University of New York at Albany (B.A. in history, 1989).

Professional
  • Member of NY Tech Meetup
  • Member of the New York Technology Council
  • Member of the New York State Bar Association and a former member of the New York State Bar Association's Special Committee on Cyberspace Law
  • Board of Trustees of the Bryant Library in Roslyn, New York
Admissions

New York

Transactions
  • Represented Energy Impact Partners LP, a fund focusing on investments in technologies and projects that optimize energy consumption and improve sustainable energy generation, in connection with its investment in the parent company of BHI Energy, an industry-leading provider of specialty services and staffing solutions to support the daily operations, routine maintenance and capital investment requirements for the power generation, oil & gas, and electricity transmission & distribution end markets.

  • Represented Energy Impact Partners LP, a fund focusing on investments in technologies and projects that optimize energy consumption and improve sustainable energy generation, in connection with its investment in the Series B Preferred Stock financing of Remix, a platform for designing and managing a city’s transportation future.

  • Represented Van Leeuwen Ice Cream, an artisan and vegan ice cream company that operates scoop shops and trucks in New York and Los Angeles and whose products are sold by over 700 retailers nationwide, in connection with its Series Seed Preferred equity financing led by Strand Equity.

  • Represented Van Leeuwen Ice Cream, an artisan and vegan ice cream company that operates scoop shops and trucks in New York and Los Angeles and whose products are sold by over 700 retailers nationwide,  in connection with its convertible note financing led by Blue Scorpion Investments, L.P.

  • Represented Energy Impact Partners LP, a fund focusing on investments in technologies and projects that optimize energy consumption and improve sustainable energy generation, in connection with its investment in the Series C-1 Preferred Stock of FirstFuel Software, Inc., a leader in business customer engagement in the energy industry.

  • Represented Energy Impact Partners LP, a fund focusing on investments in technologies and projects that optimize energy consumption and improve sustainable energy generation, in connection with its investment in the Class A Preferred Shares of Opus One Solutions Energy Corporation, a software engineering and solutions company and the developer of GridOS®, an intelligent energy networking platform which optimizes complex power flows and can deliver real-time energy management to distribution utilities and other managers of distributed energy assets.

  • Represented Global Healthcare Partners, a healthcare industry and private equity investment group, in its acquisition of a controlling interest in MPD Chemicals, a leading manufacturer of specialty chemicals primarily used in medical devices, industrial materials and pharmaceuticals, with three distinct manufacturing units: Monomer-Polymer and Dajac Labs, Silar Laboratories, and IsoSciences.

  • Represented Kali Laboratories, a developer and manufacturer of generic drugs, in the acquisition of Kali by Par Pharmaceuticals (NYSE:PRX) for $140,000,000 in cash.